PETVIVO HOLDINGS INC WTS - PETVW STOCK NEWS

PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) has appointed Rachael Schumaker as the new Business Development Manager for the Midwest Region. With over 20 years in veterinary product management and marketing, Schumaker's experience aims to enhance the introduction of the company's product, Spryng with OsteoCushion technology, to veterinarians. CEO John Lai noted this addition is crucial for achieving both short and long-term goals. PetVivo focuses on innovative medical devices for companion animals and has a product pipeline of 17 offerings, with Spryng already available for veterinarians.

PetVivo Holdings, Inc. (NASDAQ: PETV) announced the appointment of David J. Gregory as the new Regional Sales Manager for the Midwest U.S. His extensive experience in veterinary product management and distribution is expected to enhance the sales of PetVivo's product Spryng, which utilizes OsteoCushion technology for treating joint-related conditions in animals. CEO John Lai expressed confidence in Gregory's ability to drive sales, contributing to the company's goals surrounding this innovative veterinary medical device.

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) has appointed Cliff Smith as the new Regional Sales Manager for the Southeast United States. With over 25 years of experience in veterinary product distribution, Smith aims to drive sales of PetVivo's innovative veterinary medical device, Spryng, which employs OsteoCushion technology. CEO John Lai stated that Smith's expertise will be vital in achieving the company's sales objectives. PetVivo is focused on veterinary devices and has a portfolio of seventeen products, including Spryng, designed to enhance the well-being of companion animals.

PetVivo Holdings (NASDAQ: PETV, PETVW) has launched two new websites as of March 4, 2022, aimed at improving information access for pet owners, veterinarians, and investors. The websites feature modern designs and easy navigation, promoting PetVivo’s product, Spryng with OsteoCushion Technology, which aids in managing joint issues in pets. CEO John Lai expresses optimism about these resources aligning with the company's vision for growth. The websites will offer comprehensive product details and facilitate ordering.

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) will exhibit its lead product, SPRYNG^™ with OsteoCushion^™ Technology, at the Western Veterinary Conference from March 6-9, 2022. SPRYNG is an injectable device designed to alleviate lameness and joint-related issues in pets, especially osteoarthritis. The conference is expected to attract over 15,000 participants, providing PetVivo with a key opportunity for networking and commercialization. The company aims to leverage its innovative veterinary solutions to enhance treatment options for companion animals.

PetVivo Holdings, Inc. (Nasdaq: PETV) reported financial results for the three and nine months ending December 31, 2021. Revenue for Q3 2022 was $51,004, a significant increase from $507 in Q3 2021, driven by sales of Spryng™. However, the net loss rose to $1,642,129, or ($0.17) per share, compared to a net loss of $1,037,753, or ($0.16) per share, the previous year. Total revenues for the nine months reached $60,126, up from $7,303 in 2020. Despite the revenue growth, increased costs in sales, marketing, and general administration contributed to a wider net loss.

PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW) will announce its financial results on February 10, 2022, post-market close, followed by a conference call at 4:00 p.m. CT. Investors can register and access the live webcast through the company’s Investor Relations website. PetVivo focuses on innovative biomedical devices for animals, with a pipeline of 17 products and 21 patents, including its lead product, SPRYNG™, for treating osteoarthritis in dogs and horses. Disclosure of material nonpublic information will be made through its website and official communications.

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) will announce its financial results on February 10, 2022, after market close. A conference call is scheduled for the same day at 4:00 p.m. CT (5:00 p.m. ET), with a live webcast available on their Investor Relations website. The company focuses on innovative medical therapeutics for animals and holds a portfolio of 21 patents. Their lead product, SPRYNG™, designed for treating osteoarthritis in dogs and horses, was commercially launched in September 2021.

PetVivo Holdings is set to present at the Emerging Growth Conference on January 19, 2022, from 11:30 AM to 12:00 PM Eastern. During this interactive session, CEO John Lai will discuss the company’s innovative biomedical devices for pets and answer audience questions. The conference aims to connect public companies with investors and includes a wide range of growth sectors.

PetVivo focuses on launching medical therapeutics for companion animals, with its lead product, Kush, targeting osteoarthritis in dogs and horses, anticipated for commercial release later this year.